Identifier to cite or link to this item:

https://hdl.handle.net/20.500.13003/20292

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Loading...
Thumbnail Image
Identifiers

Authors

Gómez Cerezo, Jorge Francisco
Egocheaga Cabello, Isabel
Castellanos, Mar
Campuzano Ruiz, Raquel
Barrios, Vivencio
Pallarés-Carratalá, Vicente
Rodríguez, José Manuel
Morant Talamante, Nuria

Advisors

Metrics
Google Scholar
Share
Export

Date of defense

Publication date

2024

Document type

research article

Citation

Martínez López I, Gómez Cerezo JF, Gámez JM, Egocheaga Cabello I, Castellanos M, Campuzano Ruiz R, et al. Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain. Front Cardiovasc Med. 2024;11:1324537.

Volume Title

Research Projects

Organizational Units

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event. Retrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; n = 1.8 million). Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up. A total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were €11,171 during the first year and €9,944 during the second year. Patients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).

Description

Research data

Referenced by

It is version of

It is versioned by

Keywords

MeSH

DeCS

Atribución 4.0 Internacional

La licencia de este ítem se describe como Atribución 4.0 Internacional